Results 131 to 140 of about 21,169 (256)

Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?

Therapeutic Advances in Medical Oncology
The assessment of response to therapy in prostate cancer (PCa) patients is an ongoing, open issue. Prostate-specific antigen has limitations, especially in advanced metastatic PCa, which often displays intratumor variability in terms of response to ...
Martina Di Franco, Riccardo Mei, Camilo Garcia, Stefano Fanti   +3 more
doaj   +1 more source

Oncologic Outcomes of Cytoreductive Radical Prostatectomy in Patients With Synchronous Metastatic Castration‐Sensitive Prostate Cancer: A Retrospective Analysis

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objectives Local therapy for metastatic castration‐sensitive prostate cancer (mCSPC) remains controversial. This study aimed to assess the feasibility, safety, and oncologic outcomes of cytoreductive radical prostatectomy (cRP) in patients with synchronous mCSPC, with a particular focus on pathological findings.
Kento Morozumi, Kenji Numahata, Masaaki Oikawa, Masato Konno, Hiroki Kusumoto, Kuromoto Akito, Yuki Katsumata, Masahiko Sato, Yasuhiro Kaiho   +8 more
wiley   +1 more source

Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH. [PDF]

, 2019
ObjectiveTo review follow-up imaging after equivocal bone scans in men with castration resistant prostate cancer (CRPC) and examine the characteristics of equivocal bone scans that are associated with positive follow-up imaging.MethodsWe identified 639 ...
Amling, Christopher L, Aronson, William J, Cooperberg, Matthew R, De Hoedt, Amanda M, Everist, Mary M, Freedland, Stephen J, Hanyok, Brian T, Howard, Lauren E, Kane, Christopher J, Terris, Martha K   +9 more
core   +1 more source

Metastatic Prostate Cancer Masquerading as Locally Advanced Breast Cancer

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT We report a rare case of a 72‐year‐old man with prostatic adenocarcinoma metastasizing to gynecomastia breast tissue with ipsilateral axillary lymph node involvement. This presentation is notable for the absence of disseminated metastatic disease or prolonged androgen deprivation therapy.
Tess Howard, Mylestone Gobe Monna, Jasmine Zhu, Jiasian Teh, Sze Ting Lee, Grace L Chew   +5 more
wiley   +1 more source

Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects

Cancer Nexus, Volume 2, Issue 2, April 2026.
ABSTRACT Lipid nanoparticles (LNPs) represent the most clinically advanced platform for RNA delivery and have enabled major breakthroughs in vaccines and gene therapies. However, their broader application is still limited by inefficient extrahepatic delivery, immunogenicity, and insufficient control over tissue‐ and cell‐specific targeting. This review
Yu Han, Ying Wang, Xintao Gao, Yan Lei, Yantao Li, Zhiyong Tang   +5 more
wiley   +1 more source

PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer

Exploration, Volume 6, Issue 2, April 2026.
Advanced prostate cancer is highly invasive and prone to rapid metastasis, creating an urgent need for novel therapeutic strategies. We developed a PSMA‐targeting macrophage membrane‐coated nanomedicine (P‐MMCNPs@DM1). Leveraging the immune‐evasive and active‐targeting properties of macrophage membrane coating, P‐MMCNPs@DM1 effectively managed both ...
Keying Zhang, Bo Gao, Jingwei Wang, Yu Li, Chao Xu, Fa Yang, Shaojie Liu, Hongji Li, Chao Zhang, Xiangliang Meng, Zhaokun Shi, Rui Zhang, Ruili Zhang, Zhongliang Wang, Weihong Wen, Qiang Zhang, Yuankang Zou, Donghui Han, Huijie Bian, Weijun Qin   +19 more
wiley   +1 more source

Multicentre Evaluation of an AI‐Assisted Urine Test for Clinically Significant Prostate Cancer in Men Undergoing Initial Biopsy

Journal of Extracellular Vesicles, Volume 15, Issue 4, April 2026.
ABSTRACT The Extracellular Vesicles Gene‐based Prostate Score (EGPS), powered by DeepSeek, is an artificial intelligence (AI) diagnostic tool that enhances the detection of clinically significant prostate cancer (csPCa) using urinary EV‐derived gene expression, without requiring digital rectal examination (DRE).
Shaoqin Jiang, Chunguang Yang, Zhangcheng Huang, Zebang Guo, Feiting Lu, Xinwen Nian, Zhenlin Chen, Pengwei Luo, Jiawei Jiang, Xu Gao, Mengqiang Li, Fei Liu   +11 more
wiley   +1 more source

Prostate cancer brain metastases: Monitoring response to treatment with PSMA PET/CT

Radiology Case Reports
Prostate cancer brain metastases are rare but increasingly recognized with prostate-specific membrane antigen (PSMA) PET/CT. Distinguishing tumor response from postradiation changes are challenging on MRI.
Anas Al-Zubaidi, MD, Samuel Bezold, DO, Peeyush Bhargava, MD, Javier Villanueva-Meyer, MD   +3 more
doaj   +1 more source

Prostate-specific membrane antigen (PSMA) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

MedComm, Volume 7, Issue 4, April 2026.
Antibody–drug conjugates integrate antibody targeting with potent cytotoxic payloads to enable precision cancer therapy. Their clinical performance depends on coordinated optimization of engineering design, tumor antigen biology, and treatment strategy. Lessons from uro‐oncological malignancies illustrate how ADCs can be effectively developed, combined,
Bisheng Cheng, Lanqi Gong, Zongwei Wang, Peidan Peng, Kewei Xu, Hai Huang, Peng Wu   +6 more
wiley   +1 more source